{"id":3414849,"date":"2025-12-23T00:55:15","date_gmt":"2025-12-22T22:55:15","guid":{"rendered":"http:\/\/nhub.news\/?p=3414849"},"modified":"2025-12-23T11:38:06","modified_gmt":"2025-12-23T09:38:06","slug":"no-need-for-needles-us-approves-wegovy-pill-for-weight-loss","status":"publish","type":"post","link":"http:\/\/nhub.news\/de\/2025\/12\/no-need-for-needles-us-approves-wegovy-pill-for-weight-loss\/","title":{"rendered":"No need for needles? US approves Wegovy pill for weight loss"},"content":{"rendered":"<p style=\"text-align: justify;\"><b>Novo Nordisk\u2019s daily medication offers an oral alternative to blockbuster injections, with a launch expected in early January.<\/b><br \/>\nUS regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.<br \/>The US Food and Drug Administration\u2019s approval handed drug maker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly\u2019s oral drug, orforglipron, was still under review.<br \/>Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.<br \/>In recent years, Novo Nordisk\u2019s injectable Wegovy and Lilly\u2019s Zepbound have revolutionised obesity treatment globally and in the US, where 100 million people have the chronic disease.<br \/>The Wegovy pills were expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.<br \/>About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF, a non-profit health policy research group. But many more have trouble affording the costly shots.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk\u2019s daily medication offers an oral alternative to blockbuster injections, with a launch expected in early January. US regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.The US Food and Drug Administration\u2019s approval handed drug maker Novo Nordisk [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3414848,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[124],"tags":[],"_links":{"self":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/posts\/3414849"}],"collection":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/comments?post=3414849"}],"version-history":[{"count":0,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/posts\/3414849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/media\/3414848"}],"wp:attachment":[{"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/media?parent=3414849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/categories?post=3414849"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/nhub.news\/de\/wp-json\/wp\/v2\/tags?post=3414849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}